Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim

Patent Citations (64)

Non-Patent Literature (110)

• Blazer et al., J. Immunol., 1996, 157: 3250-3259.Examiner
• Odegard et al. (2009) J. immunol. 182: 4076-4084 (provided by Applicant).Examiner
• Kawamoto et al. (2006) Arthritis Res. Therapy 8:R62 (14 pages; provided by Applicant).Examiner
• Abbas, “T-cell stimulation: an abundance of B7s,” Nat Med. 5(12):1345-6 (1999).Applicant
• Aicher et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol., 164(9):4689-4696 (2000).Applicant
• Bajorath, “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model 5:169-176 (1999).Applicant
• Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol., 30(12):3707-3717 (2000).Applicant
• Bensimon et al., “Human lupus anti-DNS autoantibodies undergo essentially primary V kappa gene rearrangements,” Embo J. 13(13):2951-62 (1994).Applicant
• Brodie et al., “LICOS, a primordial costimulatory ligand?,” Curr. Biol., 10(6):333-336 (2000).Applicant
• Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol., 29(9)2863-2874 (1999).Applicant
• Buonfiglio et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol. 30(12):3463-3467 (2000).Applicant
• Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).Applicant
• Campbell et al., “Separable effector T cell populations specialized for B cell help or tissue inflammation,” Nat Immunol. 2(9):876-81 (2001).Applicant
• Chambers, “The expanding world of co-stimulation: the two-signal model revisited,” Trends in Immunology, 22(4):217-223 (2001).Applicant
• Chaouat, G. et al., (1995), “IL-10 Prevents Naturally Occuring Fetal Loss in the CBA x DBA/2 Mating Combination, and Local Defect in IL-10 Production in This Abortion-Prone Combination Is Corrected by in Vivo Injection of IFN-τ1,” J. Immunol, 154:4261-4268.Applicant
• Chapoval et al., “B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production,” Nat Immunol. 2(3):269-74 (2001).Applicant
• Cocks et al., “A novel receptor involved in T-cell activation,” Nature, 376:260-263 (1995).Applicant
• Coyle et al., “The CD28-Related Molecule ICOS Is Required for Effective T Cell-Dependent Immune Responses,” Immunity 13(1):95-105 (2000).Applicant
• Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nat. Med. 5(12):1365-9 (1999).Applicant
• Dong et al., “Cutting Edge: Critical Role of Inducible Costimulator in Germinal Center Reactions,” J. Immunol., 166(6):3659-3662 (2001).Applicant
• Dong, “ICOS co-stimulatory receptor is essential for T-cell activation and function,” Nature 409(6816):97-101 (2001).Applicant
• Eljaschewitsch et al., “Identification of a novel activation antigen on human CD4+ T cells,” Immunobiol., 194(1-3):27 (1995).Applicant
• Goding, “Monoclonal Antibodies: Principles and Practice,” 2nd Edition, Academic Press, Orlando, Florida, Chapter 8, pp. 281-293 (1986).Applicant
• Goni et al., “Structural and idiotypic characterization of the L chains of human IgM autoantibodies with different specificities,” J. Immunol. 142(9):3158-63 (1989).Applicant
• Gonzalo et al., “Cutting Edge: The Related Molecules CD28 and Inducible Costimulator Deliver Both Unique and Complementary Signals Required for Optimal T Cell Activation,” J. Immunol., 166(1):1-5 (2001).Applicant
• Gonzalo et al., “ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses,” Nat Immunol. 2(7):597-604 (2001).Applicant
• Guo et al., “Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice,” J. Immunol., 166(9):5578-5584 (2001).Applicant
• Hanzawa et al., “Characteristics of a TTH1 antibody which blocks an unknown adhesion phenomenon,” Proceedings of the Japanese Society for Immunology, vol. 24, Abstract No. W17-13 (1994) [Original Japanese and English Language Translation].Applicant
• Harlow and Lane, “Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory, p. 285 (1988).Applicant
• Heyeck et al., “Developmental regulation of a murine T-cell-specific tyrosine kinase gene, Tsk,” Proc. Natl. Acad. Sci. USA, 90:669-673 (1993).Applicant
• Houdebine “Production of pharmaceutical proteins from transgenic animals” J. Biotechnol. 34:269-87 (1994).Applicant
• Hutloff et al., “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,” Nature, 397(6716):263-266 (1999).Applicant
• Hutloff et al., “Identification and initial characterization of a novel T cell-specific cell surface activation antigen,” Immunobiol., 197(2-4):172 (1997).Applicant
• Ihara et al., “Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with type 1 diabetes in the Japanese population,” Immunogenetics 53(6):447-54 (2001).Applicant
• Iiyama et al., “The role of inducible co-stimulator (ICOS)/B7-related protein-1 (B7RP-1) interaction in the functional development of Peyer's patches,” Immunology Letters, In Press, Uncorrected Proof available online Apr. 11, 2003, http://www.sciencedirect.com/science/journal/01652478.Applicant
• Ishikawa et al., “Prediction of the Coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins in vitro,” DNA Research, 5:169-176 (1998).Applicant
• Kappel et al. “Regulating gene expression in transgenic animals” Current Opinion in Biotechnology 3:548-53 (1992).Applicant
• Kopf et al., “Inducible Costimulator Protein (ICOS) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection,” J. Exp. Med., 192(1):53-61 (2000).Applicant
• Kuchroo et al., “B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy,” Cell, 80:707-718 (1995).Applicant
• Lamhemedi-Cherradi et al., “Further mapping of the Idd5.1 locus for autoimmune diabetes in NOD mice,” Diabetes 50(12):2874-8 (2001).Applicant
• Ling et al., “Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches,” Genomics 78(3):155-68 (2001).Applicant
• Ling et al., “Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor,” J. Immunol., 164(4):1653-1657 (2000).Applicant
• Ling et al., “Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-B and human GL50 molecules,” J Immunol. 166(12):7300-8 (2001).Applicant
• Linsley, “T cell activation: you can't get good help,” Nat Immunol. 2(2):139-40 (2001).Applicant
• Liu et al. “B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo,” J Exp Med. 194(9):1339-48 (2001).Applicant
• Lucia et al., “Expression of the novel T cell activation molecule hpH4 in HIV-infected patients: Correlation with disease status”, Aids Research and Human Retroviruses 16(6):549-557 (2000).Applicant
• Mackay et al., “Follicular homing T helper (Th) cells and the Th1/Th2 paradigm,” J Exp Med. 192(11):F31-4 (2000).Applicant
• Mages et al., “Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand,” Eur. J. Immunol., 30(4):1040-1047 (2000).Applicant
• Marguet et al., “cDNA Cloning for Mouse Thymocyte-activating Molecule,” The Journal of Biological Chemistry, 267(4):2200-2208 (1992).Applicant
• McAdam et al. (2000) “Mouse inducible costimulatory (ICOS) molecule expression is increased by CD28 costimulation and regulates development of Th2 cells,” FASEB Journal, 14(6):A1169.Applicant
• McAdam, “ICOS is critical for CD40-mediated antibody class switching,” Nature 409(6816):102-105 (2001).Applicant
• McAdam, “Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells,” J. Immunol., 165(9):5035-5040 (2000).Applicant
• Metzler, W.J., “Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28,” (1997), 4(7):527-531.Applicant
• Mueller, “T cells: A proliferation of costimulatory molecules,” Curr. Biol. 10(6):R227-R230 (2000).Applicant
• Mullins et al. “Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice” Embo J., 8:4065-72 (1989).Applicant
• Mullins et al. “Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene” Nature, 344:541-44 (1990).Applicant
• Mullins et al. “Transgenesis in nonmurine species” Hypertension 22:630-33 (1993).Applicant
• Niemann “Transgenic farm animals get off the ground” Transgenic Research, 7:73-75 (1998).Applicant
• Nojima et al., “The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion,” Cellular Immunology, 152:249-260 (1993).Applicant
• Nurieva et al., “Inducible costimulator is essential for collagen-induced arthritis,” J. Clin. Invest. 111(5):701-06 (2003).Applicant
• O'Neill, “Co-stimulating allergy,” Trends Immunol. 22(4):183 (2001).Applicant
• Ogawa et al., “Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease,” J Immunol. 167(10):5741-8 (2001).Applicant
• Overbeek “Factors affecting transgenic animal production,” Transgenic Animal Technology, A Laboratory Handbook 96-98 (1994).Applicant
• Özkaynak et al., “Importance of ICOS-B7RP-1 constimulation in acute and chronic allograft rejection,” Nature Immunology 2(7):591-596 (2001).Applicant
• Pech et al., “A large section of the gene locus encoding human immunoglobulin variable regions of the kappa type is duplicated,” J. Mol Biol. 183(3):291-9 (1985).Applicant
• Poster, Kyoto International Conference Hall, Takaragaike Sakyo-ku, Kyoto, Japan (Nov. 30, 1994) [Original Japanese and English Language Translation].Applicant
• Pound, “A new T-helper cell subset?” Trends Immunol. 22(4):182-3 (2001).Applicant
• Redoglia et al., “Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor,” Eur. J. Immunol., 26(11):2781-2789 (1996).Applicant
• Richter et al., “Tumor necrosis factor-α regulates the epxpression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells, ” J. of Biological Chem. 276(49):45686-45693 (2001).Applicant
• Riley et al., “ICOS Costimulation Requires IL-2 and Can Be Presented by CTLA-4 Engagement,” J. Immunol., 166(8):4943-4948 (2001).Applicant
• Robert et al., “Antibody Cross-Linking of the Thymocyte-Specific Cell Surface Molecule CTX Causes Abnormal Mitosis and Multinucleation of Tumor Cells,” Experimental Cell Research, 235:227-237 (1997).Applicant
• Rottman et al., “The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE,” Nat Immunol. 2(7):605-11 (2001).Applicant
• Sakamoto et al., “AILIM/ICOS: its expression and functional analysis with monoclonal antibodies,” Hybridoma and Hybridomics, 20(5):293-303 (2001).Applicant
• Sato et al. (2000) “Up-regulation of inducible co-stimulator (ICOS) expression and its regulation of cytokine production in inflammatory bowel disease,” Gastroenterology, 118(4):A662.Applicant
• Schwartz, “Immunology. It takes more than two to tango,” Nature 409(6816):31-2 (2001).Applicant
• Sharpe, “Analysis of lymphocyte costimulation in vivo using transgenic and ‘knockout’ mice,” Current Opinion in Immunology, 7:389-395 (1995).Applicant
• Sigmund “Are studies in genetically altered mice out of control?” Arterioscler. Thromb. Vasc. Biol., 20:1425-29 (2000).Applicant
• Sperling et al., “ICOS costimulation: It's not just for TH2 cells anymore,” Nat Immunol. 2(7):573-4 (2001).Applicant
• Sperling “ICOS costimulation: is it the key to selective immunotherapy?,” Clin Immunol. 100(3):261-2 (2001).Applicant
• Sporici et al., “Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity?” Clin Immunol. 100(3):263-9 (2001).Applicant
• Sporici et al., “ICOS ligand costimulation is required for T-cell encephalitogenicity,” Clin Immunol. 100(3):277-88 (2001).Applicant
• Swallow et al., “B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFα,” Immunity, 11(4):423-432 (1999).Applicant
• Tafuri et al., “ICOS is essential for effective T-helper-cell responses,” Nature 409(6816):105-109 (2001).Applicant
• Tai et al., “A role for CD9 molecules in T cell activation,” J. Exp. Med., 184:753-758 (1996).Applicant
• Tamatani et al., “AILIM/ICOS: a novel lymphocyte adhesion molecule,” International Immunology, 12(1):51-55 (2000).Applicant
• Tamatani et al., “Characteristics of an antibody which induces an ICAM-1-LFA-1-independent adhesion pathway,” Proceedings of the Japanese Society for Immunology, vol. 23, Abstract No. H-160 (1993) [Original Japanese and English Language Translation].Applicant
• Tamura et al., “B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function,” Blood 97(6):1809-16 (2001).Applicant
• Tesciuba et al., “Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease,” J Immunol. 167(4):1996-2003 (2001).Applicant
• Tezuka et al., “Genetic cloning of a lymphocyte surface signal transduction molecule which induces an unknown adhesion phenomenon,” Proceedings of the Japanese Society for Immunology, vol. 24, Abstract No. W17-14 (1994) [Original Japanese and English Language Translation].Applicant
• Tezuka et al., “Identification and Characterization of Rat AILIM/ICOS, a Novel T-Cell Costimulatory Molecule, Related to the CD28/CTLA4 Family,” Biochem. Biophys. Res. Commun., 276(1):335-345 (2000).Applicant
• Tomlinson et al., “The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops,” J. Mol. Biol. 227(3):776-98 (1992).Applicant
• Wall “Transgenic livestock: progress and prospects for the future” Theriogenology 45:57-68 (1996).Applicant
• Wallin et al., “Enhancement of CD8+ T cell responses by ICOS/B7h costimulation,” J Immunol. 167(1):132-9 (2001).Applicant
• Wang et al., “Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS,” Blood, 96(8):2808-2813 (2000).Applicant
• Yoshinaga et al., “Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS,” International Immunology, 12(10):1439-1447 (2000).Applicant
• Yoshinaga et al., “T-cell co-stimulation through B7RP-1 and ICOS,” Nature, 402(6763:827-832 (1999).Applicant
• Carlesso et al., “Depletion of inducible co-stimulator (ICOS) bearing T cells inhibits expansion of T follicular helper cells (TFH) and prevents disease in a graft versus host mouse model of scleroderma” Poster Presentation, American College of Rheumatology, 2009 Annual Scientific Meeting, Oct. 19, 2009.Applicant
• Carlesso et al., “Targeted depletion of inducible co-stimulator (ICOS) bearing T cells prevents disease in a graft versus host model of scleroderma” Poster Presentation, 9th International Conference on Systemic Lupus Erythematosus, Jun. 25, 2010.Applicant
• Cook et al., “The human immunoglobulin VH repertoire,” Immunology Today (1995) 16(5):237-42.Applicant
• Faggioni et al., “Determination of the minimum anticipated biological level (MABEL) for an ADCC-enhanced inducible co-stimulator (ICOS) monoclonal antibody for the treatment of autoimmune diseases” Poster Presentation, Annual Congress of the European League Against Rheumatism, Jun. 2010.Applicant
• Ghosh et al. “Ulcerative colitis” (2000) BMJ. 320(7242):1119-23.Applicant
• Hanauer et al. “Management of Crohn's disease in adults” (2001) Am J Gastroenterol. 96(3):635-43.Applicant
• Koh et al., “A screening method of SH2 domain ligands and blockers using a solid phase binding” (1997) Cancer Lett. 120(1):1-7.Applicant
• Mendez et al. “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice” (1997) Nat Genet. 15(2):146-56.Applicant
• Mittereder et al., “ICOS is critical for follicular helper T cells (TFH)-mediated maintenance of germinal center B cells in non human primates” Poster Presentation, American College of Rheumatology, 2008 Annual Scientific Meeting, Oct. 28, 2008.Applicant
• Mittereder, “ICOS is critical for T follicular helper cell-mediated maintenance of germinal center B cells in non-human primates” FASEB Summer Research Conference—Autoimmunity, Jul. 2, 2009.Applicant
• Soderlind et al., “Domain libraries: Synthetic diversity for de novo design of antibody V-regions,” Gene (1995) 160(2):269-72.Applicant
• Takai et al. “Epitope analysis and primary structures of variable regions of anti-human FcepsilonRI monoclonal antibodies, and expression of the chimeric antibodies fused with human constant regions” Biosci Biotechnol Biochem. (2000) 64(9):1856-67.Applicant
• Taylor et al. “Unraveling Functions of ICOS Bearing T Cells: New Insights about Treating Autoimmune Disorders” Poster Presentation, Keystone Symposia on Tolerance and Autoimmunity, Feb. 21-26, 2010.Applicant
• van der Merwe et al., “CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics,” Journal of Experimental Medicine (1997) 185(3):393-403.Applicant